Stock DC4 DEXCOM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

DexCom, Inc. Share Price Berne S.E.

Equities

DC4

US2521311074

Medical Equipment, Supplies & Distribution

End-of-day quote Berne S.E.
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
118.2 CHF +7.35% Intraday chart for DexCom, Inc. -.--% -.--%
05-30 Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target MT
05-24 Declaration of Voting Results by DexCom, Inc CI

Financials

Sales 2024 * 4.33B 3.91B 340B Sales 2025 * 5.15B 4.65B 404B Capitalization 47.23B 42.6B 3,707B
Net income 2024 * 732M 660M 57.45B Net income 2025 * 910M 821M 71.42B EV / Sales 2024 * 11.2 x
Net Debt 2024 * 1.43B 1.29B 113B Net Debt 2025 * 994M 897M 78.03B EV / Sales 2025 * 9.36 x
P/E ratio 2024 *
65.7 x
P/E ratio 2025 *
53.7 x
Employees 9,550
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.62%
More Fundamentals * Assessed data

Chart DexCom, Inc.

Dynamic Chart

Latest news about DexCom, Inc.

Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target MT
Declaration of Voting Results by DexCom, Inc CI
Declaration of Voting Results by DexCom, Inc CI
Bio Conscious Announces Strategic Api Integration with Dexcom That Will Elevate the Current Level of Care for Diabetes Patients in Clinical Settings CI
Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology CI
Wall Street: the worst week of 2024 is followed by the best CF
Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 MT
Canaccord Genuity Adjusts Price Target on DexCom to $145 From $144 MT
Raymond James Adjusts DexCom Price Target to $160 From $151 MT
Dexcom's profit beats estimates on strong glucose monitor demand RE
DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
DexCom Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Gains; Shares Fall After Hours MT
Transcript : DexCom, Inc., Q1 2024 Earnings Call, Apr 25, 2024
Earnings Flash (DXCM) DEXCOM Posts Q1 EPS $0.32, vs. Street Est of $0.27 MT
Earnings Flash (DXCM) DEXCOM Posts Q1 Revenue $921M, vs. Street Est of $910.9M MT
More news

Latest transcript on DexCom, Inc.

Logo DexCom, Inc.
DexCom, Inc., Q1 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on DexCom, Inc.

Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target MT
Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 MT
Canaccord Genuity Adjusts Price Target on DexCom to $145 From $144 MT
Raymond James Adjusts DexCom Price Target to $160 From $151 MT
Dexcom Insider Sold Shares Worth $274,242, According to a Recent SEC Filing MT
More recommendations

Press releases DexCom, Inc.

Dexcom Announces Upcoming Conference Presentation BU
Dexcom Launches Innovative New Sensor as Groundbreaking Report Reveals Alarming Rates of Anxiety and Depression in Those With Type 2 Diabetes BU
DexCom : Human Rights Statement PU
DexCom: Q1 Earnings Snapshot AQ
Dexcom Reports First Quarter 2024 Financial Results BU
More press releases

News in other languages on DexCom, Inc.

Valores destacados al cierre del mercado norteamericano
Wall Street : à la pire semaine de 2024 succède la meilleure
Compañías que se deben tener muy en cuenta por técnico este martes en Wall Street
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Coinbase, Dollar General, Target, Veeva, Capita...
DexCom: nog steeds in de race
More news

Quotes and Performance

1 day+7.35%
1 month+7.35%
3 months+5.88%
More quotes

Highs and lows

1 month
118.18
Extreme 118.177
118.18
Current year
110.09
Extreme 110.088
118.18
1 year
110.09
Extreme 110.088
118.18
3 years
110.09
Extreme 110.088
118.18
5 years
110.09
Extreme 110.088
118.18
10 years
110.09
Extreme 110.088
118.18
More quotes

Managers and Directors - DexCom, Inc.

Managers TitleAgeSince
Kevin Sayer CEO
 Chief Executive Officer 66 31/10/07
Jereme Sylvain DFI
 Director of Finance/CFO 44 31/08/18
Girish Naganathan CTO
 Chief Tech/Sci/R&D Officer 47 30/09/22
Members of the board TitleAgeSince
Nick Augustinos BRD
 Director/Board Member 65 19/11/09
Mark Foletta BRD
 Director/Board Member 63 18/11/14
Eric Topol BRD
 Director/Board Member 69 08/07/09
More insiders

Company Profile

DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 72.5% of net sales.
Sector
Medical Equipment, Supplies & Distribution
Calendar
05/06/2024 - William Blair Growth Stock Conference
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for DexCom, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
118.8 USD
Average target price
150.3 USD
Spread / Average Target
+26.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-7.16% 178B
MEDTRONIC PLC Stock Medtronic plc
-1.23% 107B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.04B
CENCORA, INC. Stock Cencora, Inc.
+10.32% 44.62B
HOYA CORPORATION Stock Hoya Corporation
+8.14% 42.5B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.76% 29.99B
TERUMO CORPORATION Stock Terumo Corporation
+15.53% 25.22B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.88% 24.14B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-5.38% 23.69B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. DXCM Stock
  4. DC4 Stock